Assembly Biosciences Inc (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $49.37, for a total value of $49,370.00. Following the transaction, the director now directly owns 20,465 shares of the company’s stock, valued at $1,010,357.05. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Assembly Biosciences Inc (NASDAQ:ASMB) traded down $0.02 during mid-day trading on Thursday, hitting $44.10. The stock had a trading volume of 136,300 shares, compared to its average volume of 91,169. Assembly Biosciences Inc has a 1 year low of $11.07 and a 1 year high of $52.37.
Several hedge funds have recently bought and sold shares of ASMB. State Street Corp bought a new position in shares of Assembly Biosciences in the 2nd quarter worth about $4,234,000. JPMorgan Chase & Co. bought a new position in shares of Assembly Biosciences in the 2nd quarter worth about $3,426,000. Valeo Financial Advisors LLC bought a new position in shares of Assembly Biosciences in the 3rd quarter worth about $4,963,000. Northern Trust Corp raised its position in shares of Assembly Biosciences by 221.2% in the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock worth $4,033,000 after acquiring an additional 134,513 shares in the last quarter. Finally, AXA bought a new position in shares of Assembly Biosciences in the 2nd quarter worth about $2,477,000. 62.09% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently issued reports on the company. BidaskClub lowered Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. Finally, Jefferies Group began coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective for the company.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.